產品詳情
簡單介紹：
Anti-N4BP2L2/PFAAP5抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-N4BP2L2/PFAAP5抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-N4BP2L2/PFAAP5
Cat. Number:
Anti-N4BP2L2/PFAAP5抗體KL-18986R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PFAAP5 is a 583 amino acid nuclear protein that potentially is involved in transcriptional regulation. PFAAP5 is phosphorylated on Ser 199 in response to DNA damage, probably by ATM or ATR. Primarily expressed in bone marrow, PFAAP5 is dramatically down-regulated after exposure to arsenic compounds, an event which precedes neutropenia. PFAAP5 interacts with both Gfi-1 and Neutrophil Elastase, twoAnti-N4BP2L2/PFAAP5抗體 proteins that are implicated in neutropenia disorders. Defects in the gene encoding Neutrophil Elastase, ELA2, are the cause of cyclic haematopoiesis, which, with decreased numbers of circulating neutrophils, leads to an increased risk for opportunistic infection. Gfi1 is a transcriptional repressor that targets the ELA2 gene among others. With PFAAP5 expression, Neutrophil Elastase can potentiate repression of Gfi1 target genes, leading to the transcription of ELA2 and subsequent neutrophil differentiation. There are two isoforms of PFAAP5 that are produced as a result of alternative splicing events.
Also known as:
92M18.3 (novel protein); 92M18.3; Anti-N4BP2L2/PFAAP5抗體CG005; CG016; FLJ36195; FLJ41089; FLJ43077; N4BP2L2; NEDD4 binding protein 2 like 2; PFAAP5; Phosphonoformate immuno associated protein 5; Protein from BCRA2 region.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugatedAnti-N4BP2L2/PFAAP5抗體 synthetic peptide derived from human N4BP2L2/PFAAP5.
●
Predicted Molecular Weight: 67kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-N4BP2L2/PFAAP5抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
